The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) drugs in development market research report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued products.
GlobalData tracks 50 drugs in development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by 49 companies/universities/institutes. The top development phase for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) is phase ii with 18 drugs in that stage. The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline has 46 drugs in development by companies and four by universities/ institutes. Some of the companies in the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline products market are: 3SBio, Takeda Pharmaceutical and Nanjing IASO Biotherapeutics.
The key targets in the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline products market include Thrombopoietin Receptor, Tyrosine Protein Kinase SYK, and B Lymphocyte Antigen CD19.
The key mechanisms of action in the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline product include Thrombopoietin Receptor Agonist with nine drugs in Phase III. The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline products include four routes of administration with the top ROA being Intravenous and ten key molecule types in the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline products market including Monoclonal Antibody, and Small Molecule.
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) overview
Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose, and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on the lower legs.
For a complete picture of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
